Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?

Lees, 2009, Parkinson's disease, Lancet, 373, 2055, 10.1016/S0140-6736(09)60492-X Olanow, 2009, The scientific and clinical basis for the treatment of Parkinson disease (2009), Neurology, 72, S1, 10.1212/WNL.0b013e3181a1d44c Poewe, 2006, The natural history of Parkinson's disease, J. Neurol., 253, VII2, 10.1212/WNL.66.10_suppl_4.S2 Rascol, 2011, Milestones in Parkinson's disease therapeutics, Mov. Disord., 26, 1072, 10.1002/mds.23714 2002, Management of Parkinson's disease: an evidence-based review, Mov. Disord., 17, S1 Cesaro, 2014, Drug treatment of early-stage (de novo and “honeymoon”) Parkinson disease, Rev. Neurol. (Paris), 170, 237, 10.1016/j.neurol.2013.10.015 Kempster, 2010, Relationships between age and late progression of Parkinson's disease: a clinico-pathological study, Brain, 133, 1755, 10.1093/brain/awq059 Kempster, 2007, Patterns of levodopa response in Parkinson's disease: a clinico-pathological study, Brain, 130, 2123, 10.1093/brain/awm142 Lowin, 2011, A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK, J. Med. Econ., 14, 584, 10.3111/13696998.2011.598201 Kulisevsky, 2013, Advanced Parkinson's disease: clinical characteristics and treatment, 28, 503 Worth, 2013, When the going gets tough: how to select patients with Parkinson's disease for advanced therapies, Pract. Neurol., 13, 140, 10.1136/practneurol-2012-000463 Politis, 2010, Parkinson's disease symptoms: the patient's perspective, Mov. Disord., 25, 1646, 10.1002/mds.23135 Forjaz, 2009, The current state of the art concerning quality of life in Parkinson's disease: II. Determining and associated factors, Rev. Neurol., 49, 655 Higginson, 2012, Symptoms and quality of life in late stage Parkinson syndromes: a longitudinal community study of predictive factors, PLoS One, 7, 10.1371/journal.pone.0046327 Martínez-Martín, 2012, Quality of life and burden in caregivers for patients with Parkinson's disease: concepts, assessment and related factors, Expert Rev. Pharmacoecon. Outcomes Res., 12, 221, 10.1586/erp.11.106 Shin, 2012, Factors contributing to spousal and offspring caregiver burden in Parkinson's disease, Eur. Neurol., 67, 292, 10.1159/000335577 Ossig, 2013, Treatment of Parkinson's disease in the advanced stage, J. Neural Transm., 120, 523, 10.1007/s00702-013-1008-y Kulisevsky, 2013, Advanced Parkinson's disease: clinical characteristics and treatment. Part II, Neurología (English Edition), 28, 558, 10.1016/j.nrleng.2013.05.003 Odin, 2015, Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: consensus from an international survey and discussion program, Parkinsonism Relat. Disord., 21, 1133, 10.1016/j.parkreldis.2015.07.020 Volkmann, 2013, Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review, J. Neurol., 260, 2701, 10.1007/s00415-012-6798-6 Antonini, 2009, Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management, Expert. Rev. Neurother., 9, 859, 10.1586/ern.09.48 Pickut, 2014, Intestinal levodopa infusion: the Belgian experience, Neurol. Sci., 35, 861 Foltynie, 2013, Impact of Duodopa on quality of life in advanced Parkinson's disease: a UK case series, Parkinsons Dis., 2013, 362908 Antonini, 2009, Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease, Parkinsonism Relat. Disord., 15, S97, 10.1016/S1353-8020(09)70844-2 Stocchi, 2009, The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease, Parkinsonism Relat. Disord., 15, S68, 10.1016/S1353-8020(09)70784-9 Stocchi, 2009, The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease, Parkinsonism Relat. Disord., 15, S9, 10.1016/S1353-8020(09)70005-7 Clarke, 2010, Has drug therapy changed the natural history of Parkinson's disease?, J. Neurol., 257, S262, 10.1007/s00415-010-5716-z Deleu, 1991, Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa, Eur. J. Clin. Pharmacol., 41, 453, 10.1007/BF00626368 Nyholm, 2013, Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients, AAPS J., 15, 316, 10.1208/s12248-012-9439-1 Kurth, 1993, Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations, Neurology, 43, 1698, 10.1212/WNL.43.9.1698 Nyholm, 2003, Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets, Clin. Neuropharmacol., 26, 156, 10.1097/00002826-200305000-00010 Othman, 2014, Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets, Br. J. Clin. Pharmacol., 78, 94, 10.1111/bcp.12324 Senek, 2014, Continuous drug delivery in Parkinson's disease, CNS Drugs, 28, 19, 10.1007/s40263-013-0127-1 Abbruzzese, 2012, Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection, Funct. Neurol., 27, 147 Sensi, 2014, Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients, J. Neural Transm., 121, 633, 10.1007/s00702-013-1153-3 Wagle Shukla, 2014, Surgical treatment of Parkinson's disease: patients, targets, devices, and approaches, Neurotherapeutics, 11, 47, 10.1007/s13311-013-0235-0 Olanow, 2014, Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study, Lancet Neurol., 13, 141, 10.1016/S1474-4422(13)70293-X Slevin, 2015, Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients, J. Parkinsons. Dis., 5, 165, 10.3233/JPD-140456 Nyholm, 2005, Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease, Neurology, 64, 216, 10.1212/01.WNL.0000149637.70961.4C Isacson, 2008, Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion, Acta Neurol. Scand., 118, 379, 10.1111/j.1600-0404.2008.01049.x Fernandez, 2015, Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results, Mov. Disord., 30, 500, 10.1002/mds.26123 Clarke, 2009, Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease, Parkinsonism Relat. Disord., 15, 728, 10.1016/j.parkreldis.2009.09.005 Nilsson, 2001, Duodenal levodopa infusion in Parkinson's disease—long-term experience, Acta Neurol. Scand., 104, 343, 10.1034/j.1600-0404.2001.00153.x Antonini, 2007, Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome, Mov. Disord., 22, 1145, 10.1002/mds.21500 Antonini, 2008, Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease, Neurodegener. Dis., 5, 244, 10.1159/000113714 Eggert, 2008, Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications, Clin. Neuropharmacol., 31, 151, 10.1097/wnf.0b013e31814b113e Devos, 2009, Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease, Mov. Disord., 24, 993, 10.1002/mds.22450 Santos-García, 2010, Experience with continuous levodopa enteral infusion (Duodopa((R))) in patients with advanced Parkinson's disease in a secondary level hospital, Neurologia, 25, 536, 10.1016/j.nrl.2010.07.018 Puente, 2010, Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: impact on control of fluctuations and quality of life, Parkinsonism Relat. Disord., 16, 218, 10.1016/j.parkreldis.2009.07.015 Merola, 2011, Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson's disease, Mov. Disord., 26, 664, 10.1002/mds.23524 Busk, 2012, Long-term 24-h levodopa/carbidopa gel infusion in Parkinson's disease, Parkinsonism Relat. Disord., 18, 1000, 10.1016/j.parkreldis.2012.04.010 Fasano, 2012, Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life, Eur Rev Med Pharmacol Sci, 16, 79 Nyholm, 2012, Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease, Eur. J. Neurol., 19, 1079, 10.1111/j.1468-1331.2012.03679.x Elia, 2012, Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation, Eur. J. Neurol., 19, 76, 10.1111/j.1468-1331.2011.03437.x Pålhagen, 2012, Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease, Acta Neurol. Scand., 126, e29, 10.1111/j.1600-0404.2012.01689.x Reddy, 2012, Intrajejunal levodopa versus conventional therapy in Parkinson disease: motor and nonmotor effects, Clin. Neuropharmacol., 35, 205, 10.1097/WNF.0b013e3182613dea Santos-García, 2012, Long-term exposure to duodenal levodopa/carbidopa infusion therapy improves quality of life in relation especially to mobility, activities of daily living, and emotional well-being, Acta Neurol. Scand., 125, 187, 10.1111/j.1600-0404.2011.01523.x Zibetti, 2013, Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study, J. Neurol., 260, 105, 10.1007/s00415-012-6597-0 Antonini, 2013, Effect and safety of duodenal levodopa infusion in advanced Parkinson's disease: a retrospective multicenter outcome assessment in patient routine care, J. Neural Transm., 120, 1553, 10.1007/s00702-013-1026-9 Martínez-Martín, 2014, EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease, Mov. Disord., 30, 510, 10.1002/mds.26067 Grandas, 2014, E-DUO study: use of levodopa-carbidopa intestinal gel (LCIG) in Spanish Parkinson's disease (PD) patients [abstract], Mov. Disord., 29, 651 Cáceres-Redondo, 2014, Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease, J. Neurol., 261, 561, 10.1007/s00415-013-7235-1 Catalán, 2014 Santos, 2014, Estudio E-DUO: Uso de IICLC en pacientes españoles con enfermedad de Parkinson avanzada, 145/5088 Valldeoriola, 2016, Long-term effectiveness of levodopa-carbidopa intestinal gel in 177 Spanish patients with advanced Parkinson's disease, Neurodegener. Dis. Manag., 6, 289, 10.2217/nmt-2016-0021 Zibetti, 2014, Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience, Eur. J. Neurol., 21, 312, 10.1111/ene.12309 Dubow, 2014, Interim results of a phase 3b study assessing the safety and efficacy of levodopa-carbidopa intestinal gel on non-motor symptoms in patients with advanced Parkinson's disease [abstract], NMDP4-0179 Chang, 2015, 24h levodopa-carbidopa intestinal gel may reduce falls and “unresponsive” freezing of gait in Parkinson's disease, Parkinsonism Relat. Disord., 21, 317, 10.1016/j.parkreldis.2014.12.019 Cossu, 2015, Levodopa-carbidopa intrajejunal gel in advanced Parkinson disease with “on” freezing of gait, Neurol. Sci., 36, 1683, 10.1007/s10072-015-2234-x Antonini, 2015, Gloria study investigators coordinators. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes, Parkinsonism Relat. Disord., 21, 231, 10.1016/j.parkreldis.2014.12.012 Pålhagen, 2016, Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: an open-label prospective observational study of effectiveness, tolerability and healthcare costs, Parkinsonism Relat. Disord., 29, 17, 10.1016/j.parkreldis.2016.06.002 Timpka, 2016, Improvement of dyskinesias with L-dopa infusion in advanced Parkinson's disease, Acta Neurol. Scand., 133, 451, 10.1111/ane.12483 Băjenaru, 2016, The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience, J. Neural. Transm. (Vienna), 123, 407, 10.1007/s00702-015-1496-z Buongiorno, 2015, Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: the Barcelona registry, Parkinsonism Relat. Disord., 21, 871, 10.1016/j.parkreldis.2015.05.014 Lopiano, 2016, Motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel in Italy: an interim analysis from the GREENFIELD observational study, Neurol. Sci., 10.1007/s10072-016-2664-0 Klostermann, 2011, Benefit from jejunal levodopa in a patient with apomorphine pump, J. Neurol., 258, 311, 10.1007/s00415-010-5698-x Meiler, 2008, Rapid switch from oral antiparkinsonian combination drug therapy to duodenal levodopa infusion, Mov. Disord., 23, 145, 10.1002/mds.21800 Sánchez-Castañeda, 2010, Cognitive improvement after duodenal levodopa infusion in cognitively impaired Parkinson's disease patients, Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 34, 250, 10.1016/j.pnpbp.2009.10.021 Antonini, 2016, Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients, Mov. Disord., 31, 530, 10.1002/mds.26528 Chang, 2016, Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease, J. Clin. Neurosci., 25, 41, 10.1016/j.jocn.2015.05.059 Calandrella, 2015, Causes of withdrawal of duodenal levodopa infusion in advanced Parkinson disease, Neurology, 84, 1669, 10.1212/WNL.0000000000001500 Karlsborg, 2010, Duodopa pump treatment in patients with advanced Parkinson's disease, Dan. Med. Bull., 57, A4155 Nyholm, 2008, Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure, Clin. Neuropharmacol., 31, 63, 10.1097/WNF.0b013e3180ed449f Zibetti, 2013, Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease, Acta Neurol. Scand., 127, e28, 10.1111/ane.12075 Ricciardi, 2016, 24-hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease, Mov. Disord., 31, 597, 10.1002/mds.26564 Valldeoriola, 2014, Estudio E-DUO: Uso de IICLC en pacientes españoles con enfermedad de Parkinson avanzada. Subanálisis de duración de la enfermedad de Parkinson [Abstract], 143/5085 Antonini, 2016, Effects of age and disease duration on quality of life outcomes in advanced Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusions: a post-hoc analysis from the GLORIA registry, J. Parkinsons Dis., 6, 267 Standaert, 2016, Baseline characteristics associated with therapeutic response to levodopa-carbidopa intestinal gel treatment for advanced Parkinson's disease, J. Parkinsons Dis., 6, 172 Fernandez, 2013, Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results, Parkinsonism Relat. Disord., 19, 339, 10.1016/j.parkreldis.2012.11.020 Antonini, 2007, Continuous dopaminergic stimulation—from theory to clinical practice, Parkinsonism Relat. Disord., 13, S24, 10.1016/j.parkreldis.2007.06.002 Raudino, 2009, Long-term experience with continuous duodenal levodopa-carbidopa infusion (Duodopa): report of six patients, Neurol. Sci., 30, 85, 10.1007/s10072-009-0022-1 Pålhagen, 2013, Long-term study of intraduodenal levodopa (Duodopa®) in patients with advanced Parkinson's disease [abstract] Chaudhuri, 2011, Parkinson's disease: the non-motor issues, Parkinsonism Relat. Disord., 17, 717, 10.1016/j.parkreldis.2011.02.018 Aarsland, 2009, Neuropsychiatric symptoms in Parkinson's disease, Mov. Disord., 24, 2175, 10.1002/mds.22589 Chaudhuri, 2006, Non-motor symptoms of Parkinson's disease: diagnosis and management, Lancet Neurol., 5, 235, 10.1016/S1474-4422(06)70373-8 Martínez-Martín, 2011, The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease, Mov. Disord., 26, 399, 10.1002/mds.23462 Honig, 2009, Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life, Mov. Disord., 24, 1468, 10.1002/mds.22596 Chaudhuri, 2016, Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients: final long-term non-motor, quality of life and safety results from the GLORIA registry [abstract 2009] Storch, 2013, Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications, Neurology, 80, 800, 10.1212/WNL.0b013e318285c0ed Klostermann, 2011, Jejunal levodopa infusion in long-term DBS patients with Parkinson's disease, Mov. Disord., 26, 2298, 10.1002/mds.23833 Catalán, 2013, Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson's disease, Mov. Disord., 28, 2007, 10.1002/mds.25636 Samuel, 2015, Management of impulse control disorders in Parkinson's disease: controversies and future approaches, Mov. Disord., 30, 150, 10.1002/mds.26099 Todorova, 2015, Infusion therapies and development of impulse control disorders in advanced Parkinson disease: clinical experience after 3years' follow-up, Clin. Neuropharmacol., 38, 132, 10.1097/WNF.0000000000000091 Grandas, 2014, Estudio E-DUO: Uso de IICLC en pacientes españoles con enfermedad de Parkinson avanzada. Subanálisis de los factores asociados a la discontinuación [Abstract], 140/5084 Lang, 2016, Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials, Mov. Disord., 31, 538, 10.1002/mds.26485 Nyholm, 2006, Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease, Expert. Rev. Neurother., 6, 1403, 10.1586/14737175.6.10.1403 Jafri, 2007, Meta-analysis: antibiotic prophylaxis to prevent peristomal infection following percutaneous endoscopic gastrostomy, Aliment. Pharmacol. Ther., 25, 647, 10.1111/j.1365-2036.2007.03247.x Lipp, 2013, Systemic antimicrobial prophylaxis for percutaneous endoscopic gastrostomy, Cochrane Database Syst. Rev., 11, 10.1002/14651858.CD005571.pub3 Santos-García, 2012, Polyneuropathy while on duodenal levodopa infusion in Parkinson's disease patients: we must be alert, J. Neurol., 259, 1668, 10.1007/s00415-011-6396-z Kimber, 2016, Peripheral neuropathy and levodopa therapy in Parkinson disease: novel insights, Eur. J. Neurol., 23, 435, 10.1111/ene.12912 Merola, 2016, Peripheral neuropathy associated with levodopa-carbidopa intestinal infusion: a long-term prospective assessment, Eur. J. Neurol., 23, 501, 10.1111/ene.12846 Edwards, 2002, Predictors of burden for caregivers of patients with Parkinson's disease, J. Neurosci. Nurs., 34, 184, 10.1097/01376517-200208000-00003 Martínez-Martín, 2008, Burden, perceived health status, and mood among caregivers of Parkinson's disease patients, Mov. Disord., 23, 1673, 10.1002/mds.22106 Martínez-Martín, 2007, Caregiver burden in Parkinson's disease, Mov. Disord., 22, 924, 10.1002/mds.21355 de Fábregues, 2011, Mejoría del estado de salud y calidad de vida y reducción de la carga del cuidador en pacientes tratados con infusión continua de levodopa intraduodenal [Abstract] Epstein, 2016, Long-term PEG-J tube safety in patients with advanced Parkinson's disease, Clin. Transl. Gastroenterol., 7, 10.1038/ctg.2016.19